Skip to Main Content

CAMBRIDGE, Mass. — Sanofi Genzyme (SNY) makes most of its money developing really complicated drugs for rare diseases.

But for the next decade it will make a nice little profit in a far simpler way: by flipping its real estate.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!